A clinical trial application for varoglutamstat, or PQ912, an investigational therapy for Alzheimer’s disease, was approved in China, its developers, Vivoryon Therapeutics and Simcere Pharmaceutical Group, announced. “We are proud to have obtained [China’s Center for Drug Evaluation] CDE approval of our Clinical Trial Application of varoglutamstat which represents our strong commitment in the battle against Alzheimer’s disease,” Renhong Tang, executive vice president of Simcere, said in a press release. “We will push forward the Phase…
You must be logged in to read/download the full post.
The post Trial of Oral Varoglutamstat Cleared to Take Place in China appeared first on BioNewsFeeds.